The mycobacterial cell wall: biosynthesis of arabinogalactan and lipoarabinomannan
The mycobacterial cell wall: biosynthesis of arabinogalactan and lipoarabinomannan
复制标题
DOI：
10.1042/bst0250845
复制
发表时间：
1997-08-01
影响因子：
3.9
通讯作者：
Brennan, PJ
中科院分区：
文献类型：
--
作者：
Besra, GS;Brennan, PJ
自科赫时代之前以来，全球结核病死亡率没有显着下降；疗养院和化疗的出现极大地减少了较发达国家的结核病，但对全球问题并没有产生深远的影响[l]。根据结核菌素皮试反应性估计，世界上约三分之一的人口，即约 17 亿人，感染了结核分枝杆菌，每年出现 8-1000 万新病例，约 300 万人死于结核病 [2, 3]。全球结核病有两个方面：在美国等国家基本上得到控制，但存在一些差异，但在东南亚、非洲和太平洋地区部分地区却很猖獗，并增加了艾滋病毒感染和耐药性的并发症。开发针对结核病的新疗法并了解其发病机制需要理解细胞壁结构和生物发生的基本原理，并将这些信息应用于新药开发和其他对抗措施的挑战。
There has been no significant decrease in worldwide mortality from TB since before the time of Koch; the advent of sanatoria and chemotherapy, which drastically reduced TB in the more developed countries, has had no profound effect on the global problem [l]. It is estimated, based on tuberculin skin test reactivity, that about onethird of the world’s population, ie about 1.7 billion people, are infected with Mycobacterium tuberculosis and that, each year, 8-10 million new cases occur and about 3 million people die from TB per year [2, 3]. Global tuberculosis is two-faced: largely under control with some variations in such countries as the US, but rampant in SE Asia, Africa, and parts of the Pacific Region, with the added complications of HIV infections and drug-resistance. The development of new therapies against TB and an understanding of its pathogenesis requires comprehension of the fundamentals of cell-wall structure and biogenesis, and application of this information to the challenges of new drug development and other counteractive measures.